Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose intravenous versus intrathecal methotrexate for CNS relapse prophylaxis in diffuse large B cell lymphoma
KCT0003887Phase 3Completed
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Sep 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of methotrexate in diffuse large B-cell lymphoma (DLBCL), sponsored by JW Pharmaceutical Corporation. Started Sep 2017; status: completed.
02
Drugs
methotrexate
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on KCT0003887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003887.